Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 50 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 14849
Sealed predictions
- TRAK2 in dopamine neurons, braak+0.17 (p 0.668) → -0.05 (p 0.893)receipt 14856
Swarm cases
receipt 14856: TRAK2 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.983, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.922, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.881, n 18). could be the mix.
- skeptic
- leave-one-out range -0.10 to +0.14, sign flips 9; without severely affected donors -0.01 (p 0.983, n 18). fragile.
- cell type
- strongest in astrocytes: -0.60 (p 0.0083, n 18) vs -0.01 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TRAK2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up TRAK2 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.70 p 0.013 (needs p < 1.6e-4)
Receipts
loading the receipts